PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics
PassPort Technologies(“PPTI”) commences collaborative research with Arcturus Therapeutics(“ARCT”). In this collaborative research, PPTI and ARCT combine their ground-breaking technologies, the transdermal drug delivery technology PassPort® system and the lipid-mediated delivery technology LUNAR®, to provide new options for mRNA vaccines and therapeutics. LUNAR® technology is the enabling technology used in Kostaive™, the first self-amplifying mRNA COVID vaccine in the world approved in Japan last month on November 28, 2023.